Immuno-Oncology | Specialty

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma

April 24th 2017

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.

Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC

April 22nd 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.

Combination Therapies for Advanced Bladder Cancer

April 22nd 2017

Highlights of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Use of Immune Checkpoint Inhibitors for Bladder Cancer

April 22nd 2017

Future Treatment Options for Advanced Bladder Cancer

April 22nd 2017

Durvalumab for Treatment of Advanced Bladder Cancer

April 22nd 2017

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

April 22nd 2017

Promising Treatment Options for Advanced Bladder Cancer

April 22nd 2017

FDA Approval of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Treatment of Bladder Cancer-Immune Checkpoint Inhibitors

April 22nd 2017

FDA Approval of Durvalumab for Bladder Cancer

April 22nd 2017

Frontline Atezolizumab for Advanced Bladder Cancer

April 22nd 2017

Historic Perspective on Bladder Cancer Treatment

April 22nd 2017

Durvalumab FDA Approval for Bladder Cancer

April 22nd 2017

Bladder Cancer: Paradigm Changing Advances in Treatment

April 22nd 2017

Revolutionary Advances for Treating Urothelial Carcinoma

April 22nd 2017

Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

April 21st 2017

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

April 21st 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.